2.810EUR-0.50%Mkt Cap: —P/E: —1d ago
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hemato…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value237.93M $
Revenue (TTM)16.75M $
Gross Profit16.37M $
Net Income (TTM)-2.64M $
Revenue/Share0.2163 USD
Last Price2.810 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees46
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINES0167733015
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-37.47
EV/Revenue14.21
P/S—
P/B1.86
EPS (TTM)-0.09
EPS (Forward)—
52W Range
2.8100% of range2.910
52W High2.910 EUR
52W Low2.810 EUR
Profitability
Gross Margin97.75%
Oper. Margin30.77%
EBITDA Margin-37.91%
Profit Margin-15.76%
ROE-2.08%
ROA-2.66%
Growth
Revenue Growth106.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.34M $
CapEx (TTM)—
FCF Margin-106.21%
FCF Yield—
Net Debt-4.23M $
Net Debt/EBITDA0.67
Balance Sheet
Debt/Equity9.02
Current Ratio1.60
Quick Ratio1.59
Book Value/Sh1.544 EUR
Cash/Share0.1890 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.33.49M
Float61.45M
Insiders20.15%
Institutions0.94%
Technical
SMA 501.935 (+45.2%)
SMA 2002.058 (+36.5%)
Beta0.44
S&P 52W Chg20.80%
Avg Vol (30d)900
Avg Vol (10d)900
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—